Bora secures FDA approval for CDMO services

The Taiwanese oral solid drugmaker specialises in modified release (MR) and solvent production

picture of

Breaking News

Chinese CDMO purchases former Novartis API facility

Zhejiang Jiuzhou Pharmaceutical has committed to guarantee continuous supply of products manufactured by the former ...

Civica Rx and Exela Pharma join forces to help shortage of sodium bicarbonate

Exela has agreed to manufacture and supply sodium bicarbonate injection that has been in critically short supply in US ...

Mallinckrodt sells BioVectra CDMO for $250 million

The Canadian CDMO will continue to supply an API for UK-based Mallinckrodt's specialty brands business under a long- ...

Process optimisation with flow chemistry

WuXi STA, the Chinese CDMO with a global footprint, embraces the need to develop drugs for customers using safer, more ...

Particle Dynamics expands to upgrade CDMO services

New innovation centre includes development laboratories and pilot-scale processing rooms for spray drying, m ...

ReAgent launches biological reagent manufacturing service

The chemical manufacturer and packaging company has achieved ISO 13485 accreditation for medical devices

Case Study: Phase I to commercial in 18 months

Gabor Heltovics, Druggability Technologies CEO, talks about using Quotient Sciences to progress and scale-up an ...

Bora secures FDA approval for CDMO services

The Taiwanese oral solid drugmaker specialises in modified release (MR) and solvent production

SK Group merges affiliates to launch US-based CMO

The South Korea-based group will launched the new entity in 2020 to be called SK Pharmteco, based in Sacramento, ...

Small molecule CDMOs reacting to changing market demands

The pharmaceutical industry continues to evolve in two interesting ways: first, the development pipeline sees a variety ...

Stainless steel products in contemporary bioprocessing

ASEPCO's Mark Embury on the shift from stainless steel to single-use systems in the pharmaceutical manufacturing sector

WuXi Biologics CEO: Vaccine CDMO is the next area of growth

Dr Chris Chen launches WuXi Vaccines, announces new facility and a 20-year manufacturing contract worth US$3 billion

South Korean Celltrion picks Lonza to diversify and expand manufacturing

Existing capacity sits at 190,000 L of drug substance each year

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, ...